Ariad’s Ponatinib Shown to Aid Leukemia Patients in Study

Ariad Pharmaceuticals Inc. said its experimental leukemia drug ponatinib helped patients with a mutation resistant to other therapies in a study the company will use to seek approval from U.S. and European regulators.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.